HER2-low status in inflammatory breast cancer (IBC) is associated with hormone receptors positivity but not with pathological response to neoadjuvant chemotherapy or overall survival

被引：0
|
作者：
de Nonneville, Alexandre
Finetti, Pascal
Boudin, Laurys
Usclade, Lucas
Viens, Patrice
Viret, Frederic
Mamessier, Emilie
Goncalves, Anthony
Bertucci, Francois
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-02-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-02-07
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Hormone receptor and HER2 status: The only predictive factors of response to neoadjuvant chemotherapy in breast cancer
    Baulies, S.
    Cusido, M.
    Gonzalez-Cao, M.
    Tresserra, F.
    Fargas, F.
    Rodriguez, I.
    Ubeda, B.
    Ara, C.
    Fabregas, R.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2015, 35 (05) : 485 - 489
  • [42] Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
    Sanchez-Munoz, Alfonso
    Garcia-Tapiador, Ana Maria
    Martinez-Ortega, Esther
    Duenas-Garcia, Rosario
    Jaen-Morago, Ana
    Ortega-Granados, Ana Laura
    Fernandea-Navarro, Monica
    de la Torre-Cabrera, Capilla
    Duenas, Basilio
    Isabel Rueda, Ana
    Morales, Francisco
    Ramirez-Torosa, Cesar
    Martin-Salvago, Maria Dolores
    Sanchez-Rovira, Pedro
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (10): : 646 - 653
  • [43] Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
    Alfonso Sánchez-Muñoz
    Ana María García-Tapiador
    Esther Martínez-Ortega
    Rosario Dueñas-García
    Ana Jaén-Morago
    Ana Laura Ortega-Granados
    Mónica Fernández-Navarro
    Capilla de la Torre-Cabrera
    Basilio Dueñas
    Ana Isabel Rueda
    Francisco Morales
    César Ramírez-Torosa
    María Dolores Martín-Salvago
    Pedro Sánchez-Rovira
    Clinical and Translational Oncology, 2008, 10
  • [44] Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer
    Ustaalioglu, Bala Basak Oven
    Vardar, Fugen Aker
    Bilici, Ahmet
    Gurleyik, Gunay
    Erkol, Burcak
    Kefeli, Umut
    Aliustaoglu, Mehmet
    JOURNAL OF BUON, 2014, 19 (04): : 879 - 886
  • [45] Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy
    Shao, Yingbo
    Guan, Huijuan
    Luo, Zhifen
    Yu, Yang
    He, Yaning
    Chen, Qi
    Liu, Chaojun
    Zhu, Fangyuan
    Liu, Hui
    BREAST, 2024, 73
  • [46] Prevalence of HER2-low and HER2-zero subgroups and correlation with response to neoadjuvant chemotherapy (NACT) in patients with HER2-negative breast cancer
    Reinert, Tomas
    Sartori, Guilherme Parisotto
    Souza, Alessandra A. B.
    Pellegrini, Rodrigo
    Rosa, Mahira L.
    Rossatto, Nathalia
    Coelho, Guilherme P.
    Litvin, Isnard E.
    Zerwes, Felipe
    Millen, Eduardo
    Cavalcante, Francisco P.
    Frasson, Antonio L.
    Graudenz, Marcia S.
    Barrios, Carlos H.
    CANCER RESEARCH, 2021, 81 (04)
  • [47] Role of HER2 FISH ratios in predicting pathological complete response (pCR) to neoadjuvant systemic chemotherapy with trastuzumab in patients with inflammatory breast cancer (IBC) and non-inflammatory locally advanced breast cancer
    Kogawa, T.
    Fouad, T.
    Liu, D.
    Shen, Y.
    Masuda, H.
    Mac Gregor, M. Chavez
    Alvarez, R.
    Valero, V.
    Hortobagyi, G.
    Ueno, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S418 - S419
  • [48] The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis
    Ergun, Yakup
    Akagunduz, Baran
    Karacin, Cengiz
    Turker, Sema
    Ucar, Gokhan
    CLINICAL BREAST CANCER, 2023, 23 (06) : 567 - 575
  • [49] Pathological complete response rate and clinical outcome after neoadjuvant therapy of HER2-low breast cancer: A National Cancer Database Analysis
    Zhong, Guansheng
    Song, Dajiang
    Lou, Weiyang
    Wei, Bajin
    Chen, Yaomin
    Cui, Haidong
    Hu, Jingjing
    Dong, Huaying
    Chen, Jie
    Dai, Zhijun
    EJSO, 2023, 49 (11):
  • [50] Discordance in hormone receptor and HER2 status in breast cancer during neoadjuvant chemotherapy
    Maeda, S.
    Tohyama, H.
    Tokai, H.
    Kamohara, Y.
    Nagata, Y.
    Fujioka, H.
    Itoh, M.
    BREAST, 2011, 20 : S73 - S73
12345